EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 65 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant... October 4, 2024 Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer March 15, 2022 FDA Approvals Expand Initial Treatment Options for Multiple Myeloma January 7, 2025 Data Shows Women Are Not Getting Access To An Important Part... July 30, 2021 Load more HOT NEWS Study Finds the Cost of Treating Metastatic Breast Cancer Could More... Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced... EMA Recommends Granting a Marketing Authorisation for Fruquintinib Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early...
